GCP
NGNE icon

GSA Capital Partners’s Neurogene NGNE Stock Holding History

GSA Capital Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,936
Closed -$250K – 1943
2024
Q4 		$250K Buy
+10,936
New +$407K 0.02% 1313
2022
Q2 		– Sell
-6,394
Closed -$240K – 1671
2022
Q1 		$240K Sell
6,394
-151
-2% -$8.81K 0.03% 1052
2021
Q4 		$631K Buy
6,545
+2,774
+74% +$338K 0.08% 451
2021
Q3 		$545K Buy
+3,771
New +$577K 0.06% 649
2019
Q1 		– Sell
-3,711
Closed -$160K – 1604
2018
Q4 		$160K Sell
3,711
-5,611
-60% -$273K 0.02% 1151
2018
Q3 		$546K Buy
+9,322
New +$550K 0.03% 1029
2018
Q2 		– Sell
-1,215
Closed -$342K – 1851
2018
Q1 		$342K Buy
+1,215
New +$336K 0.02% 1261

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

GSA Capital Partners's NGNE Position: Q1 2025 in Review

GSA Capital Partners sold out of Neurogene (NGNE) in Q1 2025, closing a stake of 10,936 shares — an estimated $250K sold.

GSA Capital Partners first reported a position in NGNE in Q1 2018 and held it in 7 quarters. The position peaked at $631K in Q4 2021. 85 funds tracked by Wall St. Rank hold NGNE as of Q1 2025.

  • GSA Capital Partners reported no remaining Neurogene position as of Q1 2025 after selling out during the quarter.
  • GSA Capital Partners sold 10,936 Neurogene shares in Q1 2025, an estimated $250K.
  • GSA Capital Partners first reported a position in Neurogene in Q1 2018 and held it in 7 quarters.
  • GSA Capital Partners's Neurogene position peaked at $631K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held Neurogene as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.